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CHAPTER 13:  
THE APPLICABLE USE OF THE HPRT GENE 
MUTATION ASSAY AS A PRACTICAL TOOL IN 
MUTAGENESIS AND DNA REPAIR STUDIES  
 
 
 
Zoulikha M. Zaïr & George E. Johnson 
Swansea University, College of Medicine, Institute of Life Science, Swansea, SA2 8PP 
Email: g.johnson@swansea.ac.uk 
 
 
 
SUMMARY 
The HPRT gene mutation assay is a notable tool that detects for genotoxic substances and 
allows for the isolation and screening for inducible mutation types. As with the thymidine 
kinase (TK) mouse lymphoma assay (MLA), the HPRT gene mutation assay is considered a 
significant tool as set out in the guidelines for mammalian gene mutation tests (OECD 1997). 
Since its refinement the HPRT assay has been widely utilised in mechanistic studies using 
human knock-out cell lines for DNA repair, providing details of the mode of action (MOA) 
of the test substance. This chapter provides up-to-date methodology for carrying out the assay 
in different cell lines in the presence and absence of metabolism with relevant technical 
information and emerging advances in statistical analysis of data generated from the HPRT 
gene mutation assay.  
 
 
Key words: HPRT, Mutagenicity, DNA repair, human lymphoblastoid cells 
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1. RECOMMENDED USE OF THE HPRT ASSAY 
There are three main features of the mammalian HPRT gene mutation assay which have led 
to its wide use;  
a) The target gene is encoded on the mammalian X-chromosome and consequently it is 
easy to select for loss of function mutants in cells derived from males, which in 
mammals are heterogametic for sex chromosomes.  
b) The biochemical selection systems for loss of function with cells that survive in 
presence of 6-thioguanine (6-TG) and/or 8-azoguanine, are simple and effective 
(Caskey and Kruh 1979).  
c) Also an advantage of the HPRT gene is that mutations in the same gene can be 
compared between cell lines, experimental animals and with humans (Chen et al. 
2002).  
 
Human lymphoblastoid cell lines (Furth et al. 1981) were first used for HPRT assays. Chinese 
hamster ovary, CHO cells then became the main cell line (Moore et al. 1991) and these 
adherent cells have been the most widely used cells to date. However, the test is relatively 
flexible and the human lymphoblastoid AHH-1 and MCL-5 suspension cell lines can also be 
used (Crespi and Thilly 1984; Crespi et al. 1991). The AHH-1 cell line is very suitable for 
these experiments, and because it is heterozygous at the TK
+/-
 locus we were able to validate 
our HPRT results by carrying out both the HPRT and TK gene mutation assays alongside one 
another.  In vivo experiments can also be performed using this methodology, and mice or rats 
are commonly treated with the test substance by an appropriate route of exposure. After a 
fixation period, the rodent lymphocytes are removed and established. 
 
T-lymphocytes are particularly useful to examine because they circulate throughout many 
tissues, which allows them a greater chance to come into contact with an administered 
mutagen than cells that are permanently resident in a single tissue. T-lymphocytes are also 
long-lived in circulation and they continue to undergo cell division, which makes the 
identification of mutant cells possible. In addition to T-lymphocytes, mutant frequency has 
also been determined in many cells, including those from the spleen, kidney, thymus and 
lymph nodes. 
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2. MOLECULAR PRINCIPLES OF THE HPRT ASSAY 
HPRT is a key enzyme in the purine salvage pathway with more than 300 disease associated 
mutations reported (Torres and Puig 2007; Jinnah et al. 2010). The main being through partial 
enzyme deficiency leading to gouty arthritis and complete deficient leading to Lesch-Nyhan 
disease (Jolly 1986).  
 
The HPRT gene is located on the X-chromosome and encodes for hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) protein, which plays a key role in the purine salvage 
pathway. HPRT catalyses the transformation of purines (hypoxanthine, guanine, or 6-
mercaptopurine) to monophosphates, which are therefore cytotoxic to HPRT proficient cells. 
Cells with mutations in the HPRT gene have lost the HPRT enzyme and thus survive 
treatment with purine analogues. 
 
As large losses in the X-chromosome lead to cell lethality, only small changes, such as point 
mutations and exon deletions are detected in the HPRT gene. The spontaneous MF is also 
lower at the HPRT locus, than the TK locus, as high proportions of mutations at HPRT are 
lethal (but not at TK). These events include non-disjunction and translocation which are 
known to lead to viable TK mutants but not viable HPRT mutants. After a chemical insult, 
further multiple events are required to transform DNA changes (pro-mutagenic DNA lesions) 
into selectable phenotypes: 
a) Fixation of the mutation. 
b) Reduction of the pre-existing enzyme to a level with no biological activity. 
 
Fixation of a mutation requires the initial lesion in the DNA (i.e. adduct, strand break or 
damage to DNA dependent proteins) being translated into a DNA sequence change, such as 
point mutation, deletion or loss. For a point mutation, the mutant strand must be separated 
from the wild type strand by cell division, thus one of the progeny cells no longer produces 
active mRNA and/or protein. Point mutations can only occur after the cells have undergone 
cell division, as the lesion affecting the base may be removed or the base may be repaired by 
DNA repair. The mutation is therefore only relevant in these assays once it has been 
incorporated into both strands. For selection, the existing enzyme or mRNA must be reduced 
either by cell division or degradation to non-functional levels, so that the original phenotype 
can no longer be identified.  
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Cells are incubated in microwell culture plates with the selective agent 6-thioguanine, a 
purine analogue that is a substrate for HPRT and is toxic to non-mutant cells. A significant 
increase in mutant frequency in treatment cultures compared with controls indicates the test 
chemical has induced mutation at the HPRT locus. The average spontaneous mutant 
frequency at the HPRT locus is in the range of 10
-6
 (Johnson 2012). Using standard 
techniques, further molecular analysis of HPRT mutations can be performed, if desired. 
Mutation spectra utilising HPRT mutants from AHH-1 cells treated with the direct-acting 
genotoxicant methyl-nitrosourea (MNU) (Thomas et al. 2013) and HPRT from harvested 
liver cells from transgenic mice treated with phenobarbital (Shane et al. 2000) have provided 
invaluable insight into mutation hotpots, mutation type and frequency. 
 
 
 
 
3. MATERIALS 
3.1. Cell Lines: 
Our group in Swansea University has recently used the AHH-1 cell line to investigate the 
dose response relationships of DNA reactive genotoxic agents in the low dose region of 
exposure (Parry et al. 2005; Doak 2008). The AHH-1 cell line was very suitable for these 
experiments, and because it is heterozygous at the TK
+/-
 locus we were able to validate our 
HPRT results by carrying out both the HPRT and TK gene mutation assays alongside one 
another.   
 
Other suitable cell lines for the HPRT assay include L5178Y mouse lymphoma cells, the 
CHO, AS52 and V79 lines from Chinese hamsters (Tindall et al. 1986; Tindall and 
Stankowski Jr 1989; OECD 1997), and AHH-1, MCL-5 and TK6 human lymphoblastoid 
cells (Crespi and Thilly 1984; Moore et al. 1987; Crespi et al. 1991; Parry et al. 2005). The 
HPRT locus is on the X-chromosome and therefore primary male cell lines can also be used 
to study mutagenic effects in mice and rats (van Dam et al. 1992; Tates et al. 1994) and this 
methodology can also be used for human bio-monitoring (Albertini 2001; Parry et al. 2005). 
In this chapter we will focus on the in vitro HPRT assay mainly in human lymphoblastoid cell 
lines.  
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Each cell line requires specific culture medium and this along with the cell culture conditions 
are stated in the batch details, provided upon purchase of the cell line.  
 
 
3.2. Compounds Required For The HPRT Gene Mutation Assay: 
HAT (Hypoxanthine Aminopterin Thymidine) supplement is added to culture medium at the 
mutant cleansing stage. The aminopterin in HAT medium blocks the salvage pathway, 
leaving cells reliant on the endogenous pathway i.e. HPRT and TK, and therefore HPRT 
-
 and 
TK 
-/-
 mutants are killed. This reduces the spontaneous (background) MF values and is a 
crucial step. Concentrated HAT medium may be purchased from Sigma or GIBCO and 
diluted in sterile water. Alternatively 1 x HAT media may be made thus: 100µM 
hypoxanthine, 1 µM aminopterin, 20 µM thymidine. For freezer stock it is recommended to 
freeze aminopterin separately thus: dissolve 136 mg hypoxanthine and 48.4mg thymidine in a 
total volume of 100ml sterile water to give 100X stock. Filter sterilise and freeze 1 ml 
aliquots. Protect from light. Dissolve 4.4 mg aminopterin in a few ml of sterile 0.1N NaOH 
up to 100ml sterile water to give 100X stock. Ensure pH is 7.0, adjust with HCl if above 7.0. 
filter sterilise and store in 1 ml aliquots at -80
o
C. Protect from light. 
 
Following HAT treatment, HT (Hypoxanthine Thymidine) supplement is added to culture 
medium and both the de novo nucleotide biosynthesis pathway and the salvage pathway are 
able to function from this stage onwards. After treatment with the test compound, the HPRT
– 
mutant cells are selected for using 6-thioguanine (6-TG). HPRT
+
 cells incorporate 6-TG into 
the DNA and die, and HPRT 
–
 cells do not incorporate this toxic analogue into their DNA, 
and they survive.  
 
Ethyl-methanesulphonate (EMS) and Ethyl-nitrosourea (ENU) can be used as the positive 
controls in the absence of exogenous metabolic activation (OECD 1997). 3-
 L5178Y mouse lymphoma cells and Chinese Hamster Ovary (CHO) cells, have a published 
spontaneous MF of 2-50x10
6
 (DeMarini et al. 1988).  
  AHH-1 and MCL-5 human lymphoblastoid cells have a published spontaneous MF of 6-
80x10
6
 (Gentest 1994; Doak et al. 2007).  
 
Page 6 of 17 
 
 To avoid false negative results from the effects of metabolic cooperation, in which wild type 
HPRT+ cells cross feed killing off TG-resistant mutants, keep cell densities below the 
threshold at which this occurs. To determine the threshold, plate cells across a series of cell 
densities keeping 6-TG levels constant. The frequency should not be high enough to yield 
more than a few colonies. Suspension cells are not prone to this phenomenon and should be 
feasible at cell densities of 10
5
 cells per 96 well plate well. 
 
 For nanotoxicity studies it is advisable to use fresh HAT whenever deciding to stagger plating 
(used to make large dose-series more manageable), as cells may exhibit delayed or no cell 
revival or proliferation with free-thaw HAT stocks (Doak et al. 2012).  
Methylcholanthrene, N-nitrosodimethylamine or 7,12-dimethylbenzanthracene can be used as 
a positive control in the presence of exogenous metabolic activation (OECD 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
4. METHOD 
 
4.1 Metabolism: 
Compounds that require metabolic activation require either an exogenous source such as S9 
(treatment time of 3 to 6 hours with the test compound), or a genetically modified cell line 
such that metabolic activation is endogenous. For example MCL-5 cells are derived from L3 
cells, a subpopulation of AHH-1 cells that express a particularly high level of CYP1A1 
activity (Crespi et al. 1991; Woodruff et al. 2001). The MCL-5 cell line has also been 
transfected with two plasmids: one containing two copies of CYP3A4 cDNA and one copy of 
CYP2E1 cDNA, and a second containing one copy of each CYP1A2, CYP2A6, and 
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microsomal epoxide hydrolase cDNA (Crespi et al. 1991; Woodruff et al. 2001). Therefore 
MCL-5 cells stably express all five cDNAs and also have increased levels of CYP1A1 
compared to AHH-1 cells, and test compounds that are known to be metabolised by these 
enzymes can be tested using MCL-5 cells. Genetically modified cell lines that stably express 
metabolic enzymes can promote more stable and reliable results as there are fewer variables 
such as pH, osmolality or high levels of cytotoxicity than when adding crude cell extracts of 
liver, S9.  
 
4.2. HPRT Mutant Cleansing 
Mammalian gene mutation assays depend upon the ability to quantify mutant cells using 
selective media. The mutation frequency (MF) at each test concentration is compared to the 
control MF, and the control is a measure of the spontaneous MF. Therefore, the spontaneous 
MF should be maintained at a low and stable level within each laboratory. To decrease the 
spontaneous MF of cultures the number of HPRT 
–
 mutants are reduced using HAT 
(Hypoxanthine Aminopterin Thymidine) medium, which inhibits the endogenous de novo 
nucleotide biosynthesis pathway so that the salvage pathway is required for dNTP synthesis 
for DNA replication. Therefore, cells that are incapable of using the salvage pathway (i.e. 
HPRT 
-
 mutants) can no longer divide and undergo cell death.  
 
4.3. Treatment Protocol  
Following ‘mutant cleansing’ the cells are sub-cultured and grown for 24 hours in HT 
medium. The cells are washed and grown in normal culture medium for 3-4 days to attain 
sufficient numbers for treatment. This can be a good time to cryogenically freeze down the 
cells for storage, if for any reason the experiment needs to be carried out at a later date. 
However, one should be careful that there are no extra days added to the assay as these can 
cause clonal expansion and the spontaneous MF can be increased. 10ml treatment flasks or 6 
well plates are set up and the test chemical is added to the cultures at pre-defined 
concentrations, which should usually be separated by no more than a factor of between 2 and 
√10, and should also cover a range of high toxicity to little or no toxicity (OECD 1997). 
There are currently revisions taking place to this guideline, which currently states that “the 
maximum concentration is based on cytotoxicity then it should result in approximately 10-
20% (but not  less  than  10%)  relative  survival  (relative  cloning  efficiency)  or  relative  
total  growth”. A typical design of the HPRT assay would be testing up to 10mM or 
5,000µg/ml (OECD 1997) with a maximum of 1 insoluble concentration, because cells grow 
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in suspension and precipitate cannot be removed. However, this has recently changed for 
pharmaceutical testing which follows the guidelines produced by the International 
Conference on Harmonisation, where the top dose has been “reduced from 10mM to 1mM in 
order to reduce the number of irrelevant/false-positive in vitro findings” (ICH 2011).  
 
Treated cultures are then incubated for 4hours or 24hours depending on the half-life of the 
compound and whether S9 is added, and each test compound should be prepared and 
dissolved in the correct solvent using sources of information such as the batch guidelines or 
the Merck index. A typical design of the HPRT assay would be with and without S9 (4 hour 
treatments) plus a 24 hour treatment without S9.  
 
Each experiment is then carried out in at least duplicate, and each duplicate treatment flask is 
treated using a stock solution that is prepared each time (i.e. 2 times for a duplicate 
experiment) from the purchased product, to allow for variation in preparation procedures. 
HPRT assays usually include 4 or more concentrations with duplicate treatments per 
concentration, or in triplicate if more advanced statistical analysis is required. 
 
Negative controls must be used, and the solvent should not have a significantly different MF 
than the spontaneous MF. Positive controls must also be used (OECD 1997). Following 
chemical exposure the cells are centrifuged to remove the test medium, washed and re-
suspended in fresh culture medium for mutant expression. For the HPRT mutation assay this 
involves incubation for 13 days. This allows any mutations to become fixed and any existing 
HPRT proteins/RNA to become degraded. During the phenotypic expression period, the cells 
are sub-cultured every other day, on days 1, 3, 5, 7, 9 and 11, by centrifugation and re-
suspension of the cells in fresh culture medium. Cells can be cryogenically frozen down at 
this stage which helps when carrying out large dose response studies where large numbers of 
plates are required per dose. The day of freezing down should be recorded so that the number 
of expression period days is not altered due to this process. It is not advisable to freeze them 
down after day 9 as this is close to the time of plating, and we have previously shown this to 
increase the background mutant frequency. After the phenotypic expression period, the cells 
are added to 96-well microplates at 40% confluence (4x10
4
 cells/well for AHH-1 and MCL-5 
cells) in culture medium with selection using the toxic analogue 6-thioguanine (6-TG from 
Sigma UK) at 0.6g/ml. It is difficult to treat a sufficiently large number of cells (>105 cells 
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 Scoring colonies of attached cell lines is different from scoring colonies of suspension cell 
lines, and this should be considered when deciding whether they are defined as viable 
colonies (e.g. >20 cells diameter) or not (e.g. <20 cells diameter or the cells are dead). 
 
 Adding 6-TG can kill the colonies at a late stage of growth, and therefore you should be 
careful that you are scoring viable colonies and not dead cells. This can be determined by 
observing the morphology of the cells. For example dead AHH-1 lymphoblastoid cells are 
darker and their cell walls are also less circular than viable cells. 
per petri dish) to produce statistically powerful assays. Therefore, we make use of a 
microplate protocol to improve the sensitivity of assay.  
 
Plates are scored for colony formation after 14 days of incubation at 37
0
C in humidified 
incubator with 5% CO2. The outside wells of the 96-well microplate can dry up due to the 
long growth period in the incubator, to give false negative colony growth. Special plates can 
be purchased that have a channel for water which keeps the cells in a humid environment, or 
other methods can be designed to keep the cells in a humid environment. 
 
For the cloning efficiency (P.E) calculation, 2-200 cells/well can be plated with no selection 
at each dose. 
 
 
 
4.4. Scoring Method 
The criteria for colony counting include only scoring colonies of 20+ cells in diameter and 
ensuring separate colonies are clearly apart, thereby accounting for clonal expansion. This 
value was defined by us in Swansea and other laboratories may wish to define other scoring 
criteria. There will also be a large number of dead HPRT
+
 colonies due to 6-TG selection, 
and these must not be scored as viable colonies.   
 
 
 
 
 
4.5. Statistical Method 
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In the presence of metabolic activation and detoxification of a genotoxic compound, the 
kinetics of DNA-adduct formation is considered ﬁrst order. A biologically relevant increase 
in mutation rate which deviates from a linear response may only be observed at dose levels 
that result in saturation of the DNA repair processes. In order to determine this point of 
departure (PoD) several statistical tests may be utilised. The Genetic Toxicology Technical 
Committee (GTTC) quantitative workgroup, formally known as the International Life 
Science Institute Health and Environmental Sciences Institute (ILSI-HESI) recommend the 
use of the 1-sided Dunnett’s test for data with normal distribution and homogeneous variance, 
1-sided Dunnett’s T3 for normal distribution and heterogeneous variance and 1-sided Dunn’s 
test for non-parametric data. These tests are available in packages such as SPPS and SAS, but 
the ILSI-HESI group have recently submitted a package called ‘DRSMOOTH’ to CRAN, 
which will allow these tests and more PoD tools to be used on the open-source statistical 
software R (http://cran.r-project.org/). No observed and lowest observed genotoxic effect 
levels (NOGEL and LOGEL) can be defined using these approaches for use as PoD metrics 
for HPRT data with suitable statistical power.  
 
Other PoD methods include bilinear modelling (two lines with different slopes) such as the 
hockey stick model, which may be used to determine the ‘line of best fit’ (Lutz and Lutz 
2009) and the segmented package available in R (Muggeo 2008; Johnson et al. 2014). A 
novel package based on mgcv, which provides generalised additive modelling functions 
based on a penalised regression spline approach with automatic data smoothness function, 
can also defined as a usable PoD metric called a slope transition dose.  
 
The most well regarded approach for defining a PoD using HPRT data is the benchmark dose 
approach (Gollapudi et al. 2013; Johnson et al. 2014). Benchmark dose (BMD) analysis can 
be conducted using PROAST, the dose-response modelling software developed at the 
National Institute for Public Health and the Environment (RIVM) in the Netherlands 
(www.proast.nl; version 36.9 (Slob 2002), 2002).  BMD analysis can also be conducted using 
EPA’s Benchmark Dose Software (EPA 2013). For continuous datasets such as HPRT 
mutant frequencies, the BMDL10 and the BMDL1SD  are recommended (Johnson et al. 2014).  
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4.6. Clonal Expansion of Mutants and DNA Extraction 
Mutant HPRT
- 
colonies are removed from the 96-well microplates using Pasteur pipettes and 
re-suspended in fresh culture medium. Cultures are maintained and grown to confluence for 
sufficient numbers of cells for DNA/RNA extraction. 
 
 
4.7. HPRT Mutation Spectrum Analysis 
The HPRT gene has been characterised largely using the polymerase chain reaction (PCR), 
with multiplex PCR being used for exon deletion detection i.e. many DNA fragments (i.e. 
different exons) can be amplified simultaneously, which alongside sequencing can detect 
smaller mutations (McPherson et al. 1991). The coding region of the human HPRT gene is 
distributed over 39.8kbDNA and contains 9 coding exons. The RNA transcript can also be 
sequenced using reverse transcriptase PCR, and the resulting mutation spectrum from this 
technique provides sequence information of mRNA (cDNA) and this is least costly, with 
regards to both time and money, than multiplex PCR (Thomas et al. 2013).   
 
 
 
 
 
 
 
 
 
 
 Each replicate should have a minimum of 4 x 96-well microplates for 6-TG selection, and 2 x 
96-well microplates for cloning efficiency (viability). This can be increased if the experiment 
is designed to detect smaller changes in MF increase. For example, 100 x 96-well microplates 
for 6-TG selection and 50 x 96-well microplates for cloning efficiency are required in total for 
threshold analysis. 
 
 Cloning efficiency is a crucial step in the HPRT gene mutation assay. It is important to 
optimise the number of cells plated for this step (2-200 cells/well) for the particular laboratory 
and particular cell line. 
 
 For molecular analysis it is imperative to obtain independent mutational events. To ensure this 
plate replicate cultures at the minimum cell density required for TG-resistance. When 
harvesting cells harvest a single mutant per replicate.  
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5. CALCULATIONS 
 
Mutation Frequency and Cloning Efficiency Equations (Furth et al. 1981) 
 
Cloning Efficiency 
 
 
Cloning Efficiency % (CE) = -Ln (Xo/No) x 100 
 
 
Cell Viability (Relative Cloning Efficiency) 
 
Cell Viability % =             CE         x 100 
                                   CE of control 
 
Mutant Fraction 
 
Mutation frequency (MF)   =     -Ln (Xs/Ns)     x DF 
                                                   -Ln (Xo/No) 
 
Dilution factor (DF) =     (No. of initial cells per well) Non-selective conditions 
            (No. of initial cells per well) Selective conditions 
 
 
Xs= No. of wells without colonies 
Ns = Total no. of wells 
 
Xo= No. of wells without colonies 
No = Total no. of wells 
 
 
Worked examples:  
 
HPRT
-
 mutation frequency (MF) calculation for replicate B at 0 µg/ml MMS 
 
MF =    -Ln (1699/1800)      x          20    =   0.0577468 / 0.455115 * 0.0005 = 6.344*10
-5
 
             -Ln (1218/1920)               40000 
 
 
 
If cells have a low cloning efficiency, it can be due to [23]: 
1.) A bad batch of 96-well microplates (relatively rare) 
2.) A bad batch of horse serum (relatively rare). Make sure you use the same batch of 
horse serum throughout your experiment. 
3.) High pH on the 96-well microplates (common) due to: 
a. Opening the incubator too much during the first 4-5 days. 
b. Low CO2 setting. 
Selective conditions 
Non-selective conditions 
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c. Incorrect medium pH (should be 6.8 to 7.0 before adding serum).  
4.) Poorly growing cells.  
 
If cells have a high negative control mutant fraction, it can be due to [23]: 
1.) An artefact due to low cloning efficiency. 
2.) Improper HAT/HT treatment due to: 
a. Thymidine starvation.  
b. Inadequate aminopterin. 
3.) Exposure to a mutagen (sunlight). 
4.) Inadequate selective agent. 
 
 
6. ASSAY BENEFITS AND LIMITATIONS 
The HPRT assay is adapted for use in mammals as well as mammalian cultured cells offering 
pertinent advantages over microbial tests. These include the genomic organisation being 
similar to that of humans (and is absent in bacteria) as well as mammalian specific cell 
metabolism cannot be replicated in bacteria. 
 
As an endogenous gene HPRT is transcriptionally active and subject to transcription coupled 
DNA repair, making it an ideal assay for DNA damage and DNA repair studies alike. Indeed 
HPRT gene mutation assay detects point mutations, small insertions, frame shifts and small 
deletions and has been successfully used in mapping mutation hotspots specific to particular 
genotoxicants. As with any assay there are, however, limitations. HPRT is an X-linked gene 
and thus hemizygous in function. Detection of large deletions, non-disjunction events and 
chromosomal recombination is very poor due to such events being lethal to the cell and being 
hemizygous there is no compensation for loss of gene function resulting inevitably in cell 
death. Negative results in the HPRT assay, for example, were observed when using V79 cells 
treated with cyclopentenone (Solecki et al. 2013). The authors concluded that large 
chromosome deletions may have been the predominant form of induced mutations. This 
hypothesis is supported by investigations showing that oxidative stress is at most weakly 
mutagenic in terms of point mutations and small deletions, but mutagenic through a 
mechanism involving large rearrangements (Gille and van Berkel 1994). 
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Where the intention is to look for non-disjunction and translocation events then use of 
thymidine kinase (TK) gene as the gene of target would be a suitable alternative and has been 
reported to have a higher mutation rate relative to HPRT (Johnson 2012).  
 
 
In animal experiments it is worth remembering that dilution of mutant T-lymphocytes in 
circulation occurs as peripheral lymphocyte populations are renewed. T-lymphocyte number 
is also affected by the age of the animal (OECD 2005). As a result, sampling in the spleen 
(bone marrow may also be used) should be carefully timed to detect the maximum mutant 
frequency. It is worth noting that published studies typically focus on T-lymphocytes, which 
prevents identification of mutagenic effects that may arise preferentially in other target 
tissues. 
 
Different sensitivities of the cell lines used may also play a role in reported discrepancies 
observed for mutagenicity of several compounds of interest. These variations in cell line 
sensitivity may be due to the species of origin as well as the relative fidelity of the DNA 
repair capacity in the cells selected. If cells with reduced repair capacity are utilised for the 
HPRT assay then false positive data-sets could potentially be the result. Recent examples 
include nanotoxicity studies whereby conflicting data exists in studies that have utilised the 
HPRT assay in determining the genotoxic potential of TiO2 and carbon nanotubes (Wang et 
al. 2007; Huang et al. 2009; Asakura et al. 2010; Doak et al. 2012). 
 
 
Despite the HPRT being ideal in isolating and characterising genotoxic mutants it is not ideal 
for dose response analysis given the number of replicates and thus number of cells and doses 
required. Latest advances have seen the introduction of HPRT activity assays that may be 
used as an alternative. Such assays which include PRECICE
®
 HPRT Assay Kit from Novocib 
that allow the investigator to monitoring of HPRT activity in a convenient 96-well plate 
format using spectrophotometric analysis, after treatment with the compound of interest. 
These authors would like to see flow cytometric approaches for novel in vitro mutation tests 
coming forward, and they hold out much promise for things such as the in vitro PigA assay 
where 10,000 cells per dose can be scored in a matter of minutes from a single tissue culture 
flask, compared to hours of scoring in ~100 x 96-well plates.  
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